Why the study?
Encephalomyocarditis virus group 3 cluster caused fatal outbreaks and ongoing sporadic infections among primates in Singapore, prompting the need for a vaccine to prevent future infections.
Answers are grounded in this paper and cite their sources.
A BE-inactivated EMCV-3 vaccine candidate elicits a strong neutralizing antibody response in mice, suggesting potential for preventing EMCV-3 infections in primates.
A novel Encephalomyocarditis virus (EMCV) of the group 3 cluster (EMCV-3) was first reported in 2002 to be responsible for the deaths of orang-utans in an outbreak in the Singapore Zoo. After this first outbreak, sporadic infections among the primate population caused by EMCV-3 continued to be reported, suggesting that the virus remains prevalent in Singapore. To prevent future infections, we constructed an experimental vaccine using binary ethylenimine (BE) to inactivate the EMCV-3 virus. The immunological performance of the BE-inactivated (BEI) virus was analysed in mice and the neutralising titre of the immune sera measured against the wild-type EMCV-3. The BEI virus showed a strong immunological response in BALB/c mice at 1: 40,960 titre, suggesting that it can be used as a promising experimental vaccine candidate to prevent EMCV-3 infections.
No takes yet. Share an insight, caveat, or question.
Tong et al. (2023) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: